Kiniksa Pharmaceuticals Q1 2025 Update

Ticker: KNSA · Form: 10-Q · Filed: Apr 29, 2025 · CIK: 1730430

Kiniksa Pharmaceuticals International, PLC 10-Q Filing Summary
FieldDetail
CompanyKiniksa Pharmaceuticals International, PLC (KNSA)
Form Type10-Q
Filed DateApr 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

Kiniksa Q1 2025: Assets $1.61B, Liabilities $41.88M, Equity $1.57B. Solid financials.

AI Summary

Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial figures include total assets of $1.61 billion and total liabilities of $41.88 million as of March 31, 2025. The company reported total equity of $1.57 billion.

Why It Matters

This filing provides investors with a quarterly snapshot of Kiniksa Pharmaceuticals' financial health and operational standing, crucial for investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative events indicated.

Key Numbers

Key Players & Entities

FAQ

What were Kiniksa's total assets as of March 31, 2025?

Kiniksa's total assets were $1,605,761,800 as of March 31, 2025.

What were Kiniksa's total liabilities as of March 31, 2025?

Kiniksa's total liabilities were $41,881,319 as of March 31, 2025.

What was Kiniksa's total equity as of March 31, 2025?

Kiniksa's total equity was $1,563,880,481 as of March 31, 2025.

What is Kiniksa Pharmaceuticals International, plc's SIC code?

The Standard Industrial Classification code for Kiniksa Pharmaceuticals International, plc is 2834, Pharmaceutical Preparations.

When was Kiniksa Pharmaceuticals, Ltd. renamed to Kiniksa Pharmaceuticals International, plc?

The company's name changed from Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals International, plc on February 5, 2018.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing